To assess whether obesity is associated with progression to metastasis, prostate cancer-specific mortality (PCSM), and all-cause mortality (ACM), in patients with non-metastatic castration-resistant prostate cancer (non-mCRPC). At the population level, obesity is associated with prostate cancer mortality; however, some studies have found that higher body mass index (BMI) is associated with better long-term prostate cancer outcomes amongst men with mCRPC.
Introduction
Obesity is associated with aggressive prostate cancer at diagnosis [1] [2] [3] . We and others [4, 5] also found that obese men who underwent radical prostatectomy had a significantly increased risk of prostate cancer-specific mortality (PCSM), despite being more likely to receive postoperative radiation and androgen-deprivation therapy (ADT) [4] . Thus, the literature suggests obesity in patients with prostate cancer is linked to greater PCSM after surgery. However, amongst men with prostate cancer who progress and are treated with hormones, such as ADT, the link between obesity and longterm prostate cancer outcomes is not clear yet.
Although a few studies have analysed the effects of obesity and prostate cancer outcomes amongst patients with metastatic castration-resistant prostate cancer (mCRPC) [6] [7] [8] [9] [10] , there is not a single published study on obesity and longterm prostate cancer outcomes among non-mCRPC cases. Halabi et al. [6] analysed data from 1 296 men with advanced metastatic prostate cancer who were enrolled in nine prospective clinical trials conducted by the Cancer and Leukemia Group B (CALGB). These men had progressed despite castrate levels of testosterone, i.e. CRPC. In these men, the authors found that an elevated body mass index (BMI), as a measure of obesity, was associated with lower risks of both overall mortality and PCSM [6] . The authors speculate that obesity may lower the risk because these men had not developed cachexia yet. Similar results were seen amongst 55 men with mCRPC in Korea [9] and 63 men with mCRPC in Ireland [8] . However, a later study, including 1 006 men with mCRPC participating in a phase III international clinical trial, found BMI was not associated with overall survival [7] .
In the present study, for the first time, we analysed the association between obesity and metastasis, all-cause mortality (ACM), and PCSM amongst men with non-mCRPC. We hypothesised that whilst obesity in mCRPC may be a marker of lack of cachexia (a favourable prognostic sign), in men with non-mCRPC, where cachexia is rare, obesity would be associated with worse long-term prostate cancer outcomes, analogous to results seen in localised prostate cancer [3] .
Patients and Methods

Study Population and Design
After obtaining Institutional Review Board approval, we identified 1 292 patients with non-mCRPC (M0/Mx) from the Shared Equal Access Regional Cancer Hospital (SEARCH) database regardless of primary treatment modality at eight Veterans Affairs (VA) Medical Centres (Durham and Asheville, NC; Palo Alto, San Francisco, West LA, and San Diego, CA; Augusta, GA; Portland, OR). Data collection methods have been previously reported [11] . CRPC was defined as ≥25% PSA increase and an absolute ≥2 ng/mL increase from the post-ADT nadir while being castrated [12] . Castration was defined as a testosterone level of <50 ng/dL, bilateral orchidectomy, or continuous receipt of an LHRH agonist or antagonist. Men were required to have no evidence of metastatic disease, defined as the absence of a positive imaging test for distant metastases at or before CRPC diagnosis. All imaging tests after CRPC diagnosis were assessed for metastases. Time zero was the time of CRPC diagnosis and patients were followed-up to (i) the first positive imaging test, (ii) ACM, and (iii) PCSM, or otherwise censored at last known follow-up. PCSM was defined as having progressive, metastatic prostate cancer at the time of death and no other obvious cause of death.
Study Outcomes
Our exposure, BMI, was calculated from height and weight abstracted from the medical records at the time closest to but prior to CRPC diagnosis. We were concerned about reverse causation in that men who were previously overweight/obese may have become cachexic from their cancer resulting in weight loss, which would make the lower weight groups appear to have increased risk of adverse outcomes. While the WHO defines underweight as <18.5 kg/m 2 , few men in our cohort were underweight (eight men). Therefore, we used an expanded definition of underweight (BMI <21 kg/m 2 ) to ensure a sufficient number of men in this category to analyse and to decrease the likelihood that the normal-weight group was confounded by reverse causation. Although we explored alternative thresholds (BMI <20 and <22 kg/m . We excluded patients with missing data on race (n = 43) or BMI (n = 57) leaving a study cohort of 1 192 patients.
Statistical Analyses
Patient demographic and clinical characteristics were compared amongst BMI groups. Categorical variables were summarised using count and percentage, while continuous variables were summarised using median with interquartile range (IQR). Characteristics were compared between BMI groups using Kruskal-Wallis for continuous variables and the chi-squared test for categorical variables.
Competing risks regression was used to test the association between BMI and progression to metastases with death as the competing risk. Similarly, competing risks regression was used to model hazard of PCSM. Cox proportional hazards models were used to test the association between BMI and ACM. BMI was treated as both a continuous and categorical variable with normal weight as the reference category. When BMI was treated as a continuous variable, underweight patients (BMI <21 kg/m 2 ) were excluded to avoid concerns about reverse causation. We fit both crude models and models adjusted for age at CRPC (continuous), race (Black vs non-Black), year of CRPC diagnosis (continuous), treatment centre, primary localised prostate cancer treatment (none vs radical prostatectomy AE radiation vs radiation alone), biopsy grade group (1 vs 2-3 vs 4-5 vs unknown), Charlson Comorbidity Index [13] (0, 1, 2, ≥3) and PSA level at CRPC (continuous, log-transformed). Cumulative incidence curves were created to show the incidence of metastases or death in different BMI groups and differences in survival were tested using the log-rank test (in the absence of competing risks). All statistical analyses were performed using STATA 14.2 (Stata Corp., College Station, TX, USA). Statistical significance was defined as a P < 0.05.
Results
Patient Characteristics
Overall, 51 (4%) men were underweight, 239 (20%) were normal weight, 464 (39%) were overweight, and 438 (37%) were obese ( Table 1) . As BMI group increased, age decreased (P < 0.001) and primary treatment became more likely (P = 0.011). Underweight and obese patients had more recent year of CRPC (P < 0.001). There was no association between BMI group and race, biopsy grade group, PSA level at CRPC, or duration of follow-up. During the follow-up period, 686 patients developed metastases, 848 died, and 548 died from prostate cancer. The median (IQR) follow-up time amongst patients who did not die during the study was 34 (20-59) months.
BMI and Metastases
After excluding underweight men, there was no association between BMI as a continuous variable and metastases on univariable (P = 0.360) or multivariable analysis (P = 0.225; Table 2 ). When BMI was treated as a categorical variable, on univariable analysis, obese patients were more likely to develop metastases compared to normal weight patients (hazard ratio [HR] 1.27, 95% CI 1.03-1.58, P = 0.028), but there was no difference in risk for underweight or overweight men. After adjusting for clinical and demographic characteristics there was no longer an association between obesity and risk of metastases (P = 0.647), with age being the major factor weakening this association when covariates were added to the model one at a time. The cumulative incidence curve of BMI group and metastasis is shown in Figure 1A .
BMI and ACM
On both crude and adjusted analyses, even after excluding underweight men, higher BMI, as a continuous variable, was associated with reduced risk of ACM (crude HR 0.98, 95% CI: 0.97-0.99, P = 0.026; adjusted HR 0.98, 95% CI: 0.97-0.99, P = 0.012) ( Table 2 ). While not statistically significant, on crude analysis, underweight patients showed a trend towards increased risk of ACM compared to normal weight men (HR 1.35, 95% CI: 0.95-1.93, P = 0.097). In contrast, obese patients had a reduced risk of ACM compared to normal weight men on crude analysis (HR 0.81, 95% CI: 0.67-0.97, P = 0.025). After adjusting for multiple covariates, results were similar in that underweight patients showed a trend towards increased risk of ACM (HR 1.38, 95% CI: Table 2 ). Figure 1B shows the cumulative incidence of ACM by BMI group (logrank; P = 0.009).
BMI and PCSM
On both crude and adjusted analysis, BMI as a continuous variable was not associated with risk of PCSM (crude HR 1.00, 95% CI: 0.97-1.02, P = 0.798; adjusted HR 1.00, 95% CI: 0.98-1.01, P = 0.737) ( Table 2) . After categorising BMI, overweight and obese men did not have increased risk of PCSM (P ≥ 0.129) ( Table 2 ). Figure 1C shows the cumulative incidence of PCSM by BMI group.
Discussion
It is now well established that obesity is associated with aggressive prostate cancer and worse long-term outcomes amongst patients with localised prostate cancer [3, 5, 10, 14] . However, only a few studies have assessed the link between BMI and prostate cancer outcomes amongst men with mCRPC [6] [7] [8] [9] , and all found BMI was associated with similar or better survival. However, no study to date has investigated the association between obesity and long-term prostate cancer outcomes amongst men with non-mCRPC. Amongst these patients, we found a higher BMI was associated with reduced ACM. No associations were seen between obesity and metastasis or PCSM. These data suggest that amongst men with non-mCRPC, obesity may be unrelated to prostate cancer aggressiveness and progression, but is an overall favourable prognostic sign. This is in sharp contrast to men with localised prostate cancer, wherein obesity clearly portends a worse prostate cancer and overall prognosis [1, 10] .
Whether these results reflect that obese men are merely not cachexic or some underlying aspect of obesity that is associated with improved non-cancer outcomes, requires further study, although our present results are consistent with the general concept of the obesity paradox noted in other cancer types as well [15] .
In men with mCRPC, one study found obesity as measured by a BMI of ≥25 kg/m 2 , was associated with lower risks of overall mortality and PCSM, compared to normal weight men with mCRPC [6] . A second study found no link between obesity and prostate cancer outcomes; however, these were patients participating in a phase III clinical trial of docetaxel vs mitoxantrone and thus all were treated with chemotherapy [7] . In a small study of 55 Korean patients with mCRPC who received docetaxel, a higher BMI (≥23 kg/m 2 ) was associated with decreased PCSM [9] . A report from a small study of 63 Irish patients with mCRPC, where BMI was cut at 25 kg/m 2 , found that higher BMI was a significant predictor of longer overall survival [8] . Thus, the literature to date suggests that unlike localised disease, for men with mCRPC obesity is associated with similar or better overall survival. However, to our knowledge, our present study is the first to analyse the association of obesity on prostate cancer outcomes amongst patients with non-mCRPC. Our present results, analogous to prior studies of men with mCRPC [6, 8, 9] , showed that obesity is associated with lower ACM risk, although we found no association with prostate cancer-specific outcomes.
Although obesity was linked with improved overall survival, in our present study amongst patients with non-mCRPC, obese men were at equal risk of PCSM and metastases compared to non-obese men. As such, obesity was selectively associated with improved non-prostate cancer outcomes and unrelated to prostate cancer outcomes. We propose several The interaction between BMI (continuous) and Charlson Comorbidity Index (0, 1, 2, ≥3) was P = 0.849 for metastases, P = 0.672 for ACM, and P = 0.942 for PCSM. 
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© 2018 The Authors BJU International © 2018 BJU International possible explanations for our present findings. First, while tumour-related cachexia is unlikely in non-mCRPC, patients may have cachexia from other causes such as heart disease, chronic obstructive pulmonary disease, and/or other types of cancer. Thus, a greater BMI may demonstrate a current lack of cachexia but also perhaps provide some protection from future cachexia allowing patients to live longer. We also observed that risks of metastasis, ACM and PCSM, although not statistically significant, were greatest in underweight men compared to normal weight men, arguing this could be in part cachexia-related. Second, the null associations of obesity with prostate cancer outcomes could be related to competing biological factors of obesity that both may drive and inhibit prostate cancer. Obese men are prone to insulin resistance and hyperinsulinaemia conditions, which drive a pro-insulin and pro-inflammation environment, which could promote prostate cancer tumours [16] . However, obesity also alters hormone levels. Specifically, testosterone is converted to oestrogen in the fat. It is well-known that obese men have higher oestrogen levels. Although these would be reduced dramatically in castrated men, as testosterone levels are not zero in castrated men, oestrogen levels are also not zero and presumably higher in obese men. Given oestrogen may suppress CRPC growth [17] , it is possible the anti-prostate cancer effects of higher oestrogen off-set the pro-prostate cancer effects of higher insulin leading to an overall null effect of obesity on prostate cancer in men with CRPC.
The present study has several strengths including the large number of patients with non-mCRPC and prostate cancer events, which allowed us to both stratify analysis by BMI categories and adjust for clinicopathological features. However, the present study had a few limitations including not having data on further treatments after CRPC diagnosis, although with a median year of non-mCRPC diagnosis of 2006-2009 and median follow-up of 2-3 years, most men were managed in an era prior to modern mCRPC drugs and these agents were unlikely to have largely influenced our results. Likewise, no data reflecting changes in nutritional and lifestyle regimens prior to CRPC were available. No data were available on serum hormones to relate to obesity to test whether circulating oestrogen and/or testosterone influenced prostate cancer outcomes in our present cohort. Height and weight data were abstracted from medical records, which were recorded in real-time. While we do not know if the values were measured or self-reported, we have previously shown a very high correlation between measured and selfreported heights and weights within the VA system [18] . However, not all men had height and weight data at the exact time of CRPC diagnosis. As such, it is possible that some men may have gained or lost weight, although we have shown for men on hormonal therapy after the first year, weight tends to be stable [19] . How this may have influenced our results is unknown. Also, as few men in our present cohort were underweight according to the WHO definition (BMI <18.5 kg/m 2 ; n = 8), we used an expanded definition of underweight (BMI <21 kg/m 2 ) to ensure a sufficient number of men in this category to analyse. Although this could be seen as a limitation, by doing this we decreased the likelihood that the normal weight group was confounded by reverse causation. In addition, when we explored alternative thresholds (BMI <20 and <22 kg/m 2 ) results were similar. Moreover, results were derived from men from a few VA centres in the USA -to what degree these data are representative of all men with prostate cancer requires further study. Furthermore, ACM and prostate cancer deaths were hand abstracted from medical records based upon individual level chart reviews, supervised by a senior prostate cancer clinician (S.J.F.). As there is no reason to believe BMI should influence the accuracy of the determination of the cause of death from the chart reviews, inaccuracies in capturing these data should bias the results to the null, not create positive associations. Finally, our present results require validation in other datasets and if validated, then future studies are needed to explain why obesity is associated with more aggressive cancers at diagnosis, but better outcomes in late-stage disease.
Conclusions
This is the first study to investigate prostate cancer outcomes amongst men with non-mCRPC. We found obesity to be associated with better overall survival, similar to results from men with mCRPC, although no associations were found with prostate cancer-specific outcomes, such as metastases and PCSM. While it is possible that higher BMI merely reflects a lack of tumour-induced cachexia, the degree of tumour-related cachexia for men with non-mCRPC is likely low. Alternative explanations are needed to better understand the paradox that in men with early stage disease, obesity portends a poor prognosis, whilst in men with CRPC obesity is either unrelated to prostate cancer outcomes or associated with lower risk of
